Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.68 |
| ▸ | HTR7 | P34969 | 4/20 | 0.64 |
| ▸ | HTR1A | P08908 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | GFER | P55789 | 1/20 | 0.63 |
| ▸ | ATM | Q13315 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | GRM5 | P41594 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9988385 | 0.86 | MAPT (0.76) | MAPTLMNANPSR1ALDH1A1HTR7 | |
| SCHEMBL12916432 | 0.86 | MAPK1 (0.59) | MAPTLMNANPSR1ALDH1A1MEN1 | |
| SCHEMBL30528252 | 0.85 | MAPT (0.86) | MAPTLMNANPSR1ALDH1A1HTR7 | |
| SCHEMBL10981623 | 0.84 | ME2 (0.64) | MAPTLMNAALDH1A1KMT2AGFER | |
| SCHEMBL2867356 | 0.84 | AKR1C3 (0.69) | MAPTLMNAALDH1A1HTR7HTR1A | |
| SCHEMBL7840682 | 0.84 | MAPT (0.72) | MAPTLMNANPSR1ALDH1A1HTR7 | |
| SCHEMBL10976043 | 0.83 | MAPT (0.82) | MAPTLMNANPSR1ALDH1A1HTR7 | |
| SCHEMBL264542 | 0.83 | MEN1 (0.74) | ALDH1A1HTR7HTR1AMEN1KMT2A | |
| SCHEMBL12916359 | 0.83 | HTT (0.59) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL2878977 | 0.83 | POLB (0.69) | MAPTLMNAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368608-A1 | SELECTIVE HDAC6 INHIBITOR | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2025-12-04 | — | — | US | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2023-09-26 | — | — | US | disclosed |
| WO-2022203399-A1 | ADENOSINE A2A RECEPTOR ANTAGONIST AND USE THEREOF | 주식회사 스탠다임 | 2022-09-29 | — | — | WO | disclosed |
| WO-2022129256-A1 | SELECTIVE HDAC6 INHIBITOR | ROYAL COLLEGE OF SURGEONS IN IRELAND (IE) | 2022-06-23 | — | — | WO | disclosed |
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2021-06-24 | — | — | US | disclosed |
| US-10980806-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2021-04-20 | — | — | US | disclosed |
| US-10544110-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190022093-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2019-01-24 | — | — | US | disclosed |
| WO-2017165822-A1 | SMALL MOLECULE INHIBITOR OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2017-09-28 | — | — | WO | disclosed |
| EP-2452939-B1 | PIPERAZINYL 3-AMINOPYRROLIDINE DERIVATIVES AS A CCR2 ANTAGONIST | YANG JI CHEMICAL CO LTD (KR) | 2014-03-26 | — | — | EP | disclosed |
| US-8575173-B2 | Piperazinyl 3-aminopyrrolidine derivatives as a CCR2 antagonists | YANG JI CHEMICAL CO., LTD. (KR) | 2013-11-05 | — | — | US | disclosed |
| US-8299072-B2 | Pyrazolylmethylamine compounds as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2012-10-30 | — | — | US | disclosed |
| US-20120190689-A1 | PIPERAZINYL 3-AMINOPYRROLIDINE DERIVATIVES AS A CCR2 ANTAGONIST | YANG JI CHEMICAL CO., LTD. (KR) | 2012-07-26 | — | — | US | disclosed |
| EP-2452939-A2 | PIPERAZINYL 3-AMINOPYRROLIDINE DERIVATIVES AS A CCR2 ANTAGONIST | Yang Ji Chemical Co., Ltd. (KR) | 2012-05-16 | — | — | EP | disclosed |
| US-7790726-B2 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100094006-A1 | NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-04-15 | — | — | US | disclosed |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-03-22 | — | — | US | disclosed |
| US-4510142-A | ANTIINFLAMMATORY OR ANALGESIC AGNET | PIERRE FABRE S.A. (FR) | 1985-04-09 | — | — | US | disclosed |
| EP-0077720-B1 | BIPHENYL ALKYL CARBOXYLATED DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINES | PIERRE FABRE S.A. (FR) | 1984-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186963-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, NR0B1, NCOA3 | MAPT 4386/4885LMNA 4118/4885NPSR1 895/4885 |
| US-20250368608-A1 | SELECTIVE HDAC6 INHIBITOR | HDAC6, HDAC3, HDAC1 | MAPT 557/4885LMNA 4049/4885NPSR1 89/4885 |
| US-20190022093-A1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, NR0B1, NCOA3 | MAPT 4364/4885LMNA 4166/4885NPSR1 996/4885 |
| US-20120190689-A1 | PIPERAZINYL 3-AMINOPYRROLIDINE DERIVATIVES AS A CCR2 ANTAGONIST | CCR2, CCR1, CCR9 | MAPT 4403/4885LMNA 4471/4885NPSR1 220/4885 |
| US-11766433-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | MAPT 4362/4885LMNA 4159/4885NPSR1 979/4885 |
| US-10980806-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | MAPT 4362/4885LMNA 4159/4885NPSR1 979/4885 |
| US-10544110-B2 | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer | AR, NR0B1, NCOA3 | MAPT 4391/4885LMNA 3940/4885NPSR1 885/4885 |
| US-20070066583-A1 | Monocyclic and bicyclic compounds and methods of use | CCR1, CCR3, CCR4 | MAPT 3597/4885LMNA 2708/4885NPSR1 799/4885 |
| US-20100094006-A1 | NOVEL PYRAZOLYLMETHYLAMINE COMPOUNDS AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | CACNA1I, CACNA1C, ORAI1 | MAPT 1118/4885LMNA 1651/4885NPSR1 1352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.